BERNSTEIN, BARRY,DUTTA, SANDEEP,LIU, WEI,PODSADECKI, THOMAS J.,CAMPBELL, ANDREW L.,MENON, RAJEEV M.,LIN, CHIH-WEI,WANG, WIAN-LI,AWNI, WALID M.
申请号：
TW103109530
公开号：
TW201511759A
申请日:
2014.03.14
申请国别(地区):
TW
年份:
2015
代理人:
摘要：
The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.本發明之特徵在於用於治療HCV之無干擾素及利巴韋林(ribavirin)之療法。較佳地，該治療係持續較短之治療時間，例如不超過12週。在一個態樣中，該治療包括在無干擾素及利巴韋林之情形下向感染HCV之個體投與至少兩種直接作用性抗病毒劑，其中該治療持續12週，且該至少兩種直接作用性抗病毒劑包含(a)化合物1或其醫藥上可接受之鹽及(b)化合物2或其醫藥上可接受之鹽。
